Cullinan Oncology Inc
For the period ended Dec 31, 2023. Filed Mar 14, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 14, 2024
CGEM$11.23-4.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders' Equity
(in thousands, except share amounts)
| Preferred Stock · Common Stock · AdditionalPaid-In · AccumulatedOtherComprehensive · Accumulated · NoncontrollingInterests in · TotalStockholders’ | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Amount | Capital | Loss | Deficit | Subsidiaries | Equity | |
| Balances at December 31, 2021 | — | $— | 44,292,102 | $4 | $584,714 | $(838) | $(158,909) | $403 | $425,374 |
| Contributions from noncontrolling interests | — | — | — | — | — | — | — | 1,527 | 1,527 |
| Acquisition of noncontrolling interests | — | — | — | — | (32,706) | — | — | (575) | (33,281) |
| Net issuance of common stock under equity-based compensation plans | — | — | 1,504,347 | 1 | 6,019 | — | — | — | 6,020 |
| Equity-based compensation | — | — | — | — | 27,293 | — | — | 664 | 27,957 |
| Unrealized loss on investments | — | — | — | — | — | (1,763) | — | — | (1,763) |
| Net income (loss) | — | — | — | — | — | — | 111,214 | (2,019) | 109,195 |
| Balances at December 31, 2022 | — | — | 45,796,449 | 5 | 585,320 | (2,601) | (47,695) | — | 535,029 |
| Contributions from noncontrolling interests | — | — | — | — | — | — | — | 2,131 | 2,131 |
| Issuance of common stock | — | — | 3,310,000 | — | 38,388 | — | — | — | 38,388 |
| Issuance of preferred stock in exchange for common stock | 647,500 | — | (6,475,000) | (1) | 1 | — | — | — | — |
| Net issuance of common stock under equity-based compensation plans | — | — | 268,634 | — | 538 | — | — | — | 538 |
| Equity-based compensation | — | — | — | — | 30,438 | — | — | — | 30,438 |
| Unrealized gain on investments | — | — | — | — | — | 2,472 | — | — | 2,472 |
| Net loss | — | — | — | — | — | — | (153,162) | (1,939) | (155,101) |
| Balances at December 31, 2023 | 647,500 | $— | 42,900,083 | $4 | $654,685 | $(129) | $(200,857) | $192 | $453,895 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.